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In 1969 a decree of the Ministry of Health, which
incorporated a list of essential drugs identified by their
generic names, reached the statute book in Chile.
Much technical work and political preparation had
preceded this event. The decree had two main
purposes. It was intended to rationalise the use of
pharmaceutical products and to benefit the consumers,
including the health service, by reducing the cost of
drugs. This article deals with the historical background
to this development, discusses some of the problems in
bringing it about, and briefly examines the more
recent fate of this system created earlier than many in
the developing world.
Historical Background
Before 1924, health care in Chile was provided by
several organisations, the most important being the
charitable Beneficiencia. It managed almost all the
hospitals and health services which were the
responsibility of local councils and the government's
Direccion General de Sanidad.
In 1924, Ezequiel Gonzalez Cortes, a distinguished
professor of medicine who was also a Senator,
promoted workers' health protection legislation
inspired by the German Krankenkasse. This led to the
approval of the law on compulsory workers insurance,
the Seguro Obrero Obligatorio (SOO). Together with
the corresponding fund (the Caja de Seguro Obrero or
Manual Workers Fund) it formed the basis of an
organised health system for manual workers and the
beginning of social security in Chile [Valdivieso and
Juricic 1970].
The Manual Workers Fund organised its own
outpatient services through health centres and by
means of domiciliary visits. For hospital treatment it
arranged a covenant with the Beneficiencia, which
enabled the Fund to keep costs down. Those affiliated
to the Manual Workers Fund acquired the right to
curative and preventive health care for themselves and
their families, as well as illness and retirement benefits.
Doctors had absolute freedom in the drugs they
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prescribed, and the patients received free prescriptions.
It soon became evident that the procedure was being
abused. The Fund's management board sought
outside advice, and it was proposed that a list be
drawn up of those drugs which were used most
frequently and could be produced locally on an
industrial basis. The outcome was the Arsenal
Farmacológico of the SOO. Its main purpose was to
eliminate, wherever possible, obsolete formulae for
extemporaneous preparations. At this time - the end
of the I930s therapy was still mainly symptomatic,
and as there were relatively few drugs that were
pharmacologically active, many placebos were being
used.
The next important step was the purchase by the
Manual Workers Fund of a pharmaceutical company,
the Laboratorio Chile. From then onwards this
company concentrated on producing the drugs from
the Arsenal Farmacológico of the SOO.
These developments constituted the beginnings of a
partial socialisation of health care in Chile. There can
be no doubt that the results were satisfactory for the
Manual Workers Fund: expenditure was controlled
and there was no deterioration in the medical services
provided.
During the l940s and 1950s came the discovery of a
wide range of new pharmaceuticals, notably the
antibacterial drugs. These were spectacularly effective
in controlling diseases that had been crippling and
fatal before, but they also often caused adverse
reactions in patients. Self-medication increased, and
this was one of the factors that brought about a rise in
the unjustified use of drugs. As a result, departments
of pharmacological surveillance were set up in many
hospitals in Chile.
In 1952, the Beneficiencia with its hospitals, the
medical services of the Manual Workers Fund, the
municipal health services, and the Bacteriological
Institute were all incorporated into one organisation
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dependent on the Ministry of Health, the servicio
nacional de salud (SNS). The SNS took responsibility
for preventive health care for the country's entire
population. It was also to provide curative services
(including rehabilitation) for all manual workers and
peasants and their families. These represented
together some 70 per cent of the Chilean population.
The SNS came to administer 86 per cent of the
country's hospital beds, and employed - on a full- or
part-time basis 89 per cent of the country's medical
doctors.
In 1961, as pharmaceuticals began to emerge as an
issue, the SNS decided to replace a considerable
number of patented pharmaceutical products used in
its hospitals by the equivalent generic drugs. The
resources saved as a result turned out to be very
considerable indeed.
The Ministry of Health Intervenes
At the beginning of 1965 the Minister of Health in the
government of the newly elected President Frei,
outlined for the Senate Health Commission the
government's health policy proposals for its six year
period of office, These included the decision to bring
about substantial changes in the systems of supply and
marketing of pharmaceutical products. It was on this
occasion that the idea of the Formulario Nacional de
Medicamentos, the National Formulary (NF), was first
mooted.
The pharmaceutical problem in Chile had various
roots. Some of these were specific to the country and
its economic situation, and others were related to the
commercial practices of the transnational pharma-
ceutical industry. Price rises of pharmaceutical
products had always had social repercussions in the
country similar to those for basic goods like bread or
sugar - whether these resulted from inflation, real
increases in costs, or a combination of both. The
government concluded that it was its responsibility to
control the costs of pharmaceuticals.
A price control policy had already been in operation
for a number of years. Prices were fixed in relation to
production costs - as declared, or sometimes as
established after an investigation. However, it soon
became obvious that for this type of product the
procedure was purely fictional. Reliable data on the
costs of pharmaceutical products were just not
available, the more so as the main production units of
this industry in Chile were subsidiaries of multinational
companies, whose prices for basic drugs and certain
other inputs were set arbitrarily by their head offices.
As for the national companies which produced
finished drugs, these frequently resorted to double
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invoicing, so that it was equally difficult to assess real
production costs. Moreover, the use of brand names
and patents nullified the potentially beneficial effect of
the interplay of supply and demand on market prices.
With the operation of monopolistic and oligopolistic
forces, price setting had become discretionary.
Problems such as these were also brought out during
the hearings on the pharmaceutical industry of the
United States Senate Subcommittee on Monopolies,
under the chairmanship of Senator Kefauver, which
focused its attention on the peculiar conditions
characterising production and trade in that industry in
relation to existing anti-trust legislation in the United
States. Witnesses before the Subcommittee emphasised
the high rate of profit in the industry, given the lack of
effective price competition brought about by patent
protection and vast promotional expenditures for
proprietary drugs, especially where generic alternatives
were available on the market. These hearings occurred
when the formulation of a pharmaceutical policy in
Chile was already well advanced. They did, however,
play an important role in the development of events, as
decision makers in Chile became convinced that the
implementation of such a policy was indeed a matter
of urgency.'
The National Formulary Bill
Mention has already been made of the benefit to the
SNS of replacing brand name products by generic
drugs wherever possible in its pharmacies. Instituting
a list of generic drugs greatly reduced hospital
expenditure, but other measures were needed to deal
with the problem outside the hospitals, especially
because non-hospital expenditure accounted at that
time for more than four-fifths of the national
expenditure on drugs. A survey carried out in Santiago
in 1964 had shown that on average over 40 per cent of
personal health expenditure went on pharmaceutical
products. The proportion was even higher among the
poorer sections of the population and rose to 75
per cent for the lowest income bracket [Diaz 1966]. So
in December 1965 the Ministry of Health installed a
Commission, made up of senior academics from
relevant departments of the medical school of the
University of Chile and representatives of the various
health professional associations and of the public
health services, to advise on a national formulary.
The Minister of Health gave the Commission, at its
opening session, the following terms of reference:
After an exhaustive study of the drug problem, this
Ministry is convinced that the present system of
supplying the country with drugs needs to be
'The report of the hearings can be consulted in United States, Senate,
1968.
urgently modified. Their use needs to be
rationalised, in order to ensure scientific efficacy
and economic benefits. Not all pharmaceutical
products on the market have a recognised
therapeutic value, and it is well known that many of
them have none at all. The number of genuine
ethical drugs is vastly lower than the total supplied
by the pharmaceutical industry to the market.
[There are as well, too many] combinations of
drugs that can hardly be justified, or that are even
absolutely useless. Yet their use increases total
health expenditure. The Commission will have as
its task to recommend a list of essential -
indispensable - drugs, which are needed in an
efficient therapy that accords with the present state
of medical knowledge. A brief explanatory
statement is to accompany each group of drugs, in
order to provide better information for the medical
profession. [Ministério de Salud, 19661
The Commission was given permanent status, so that
the national formulary could be updated from time to
time, in the light of scientific advances.
The institutionalisation of the NF Commission as a
permanent body had a number of important
consequences. In conjunction with the authorities of
the SNS it was given the role of deciding on the
licensing of all new pharmaceutical products to be
introduced in the country. It was thereby in a position
to influence the rationalisation of drug use. Perhaps
even more important, however, was the standing of
the Commission's members in the scientific community
and the participation of the Chilean Medical
Association (the Colégio Medico de Chile) in its
deliberations. This meant that the pharmacological
and therapeutic information on each group of drugs
published in successive editions of the NF had a
chance of being taken seriously by physicians
throughout the health sector. In this way a
counterweight might be provided to the commercial
publicity for the proprietary products in the private
sector. So there was a fair chance that the NF drugs
would also find their way into general use as a result of
new prescribing patterns. A simple list of generics
could have been imposed upon the hospitals by
administrative fiat of the Ministry of Health.
However, the chance of influencing the wider pattern
of drug use in the country would have been lost.
The criterion for inclusion in the NF was that a
product should 'have a universally recognised
therapeutic value' [Ministério de Salud 1969:35]. Not
all the excluded drugs were seen as lacking therapeutic
effectiveness; some were left out because they were
broadly interchangeable with drugs that were included
but which were regarded as having the balance of
advantages.
In summary, the NF was part of a policy that
attempted to rationalise the use of drugs, to lower their
costs without allowing deterioration in the quality,
and to facilitate their supply. It was given legal
sanction in January 1969 and the first edition was
published shortly afterwards.
Upgrading of the Laboratorio Chile
During the two and a half years it took to compile the
NF, measures were taken to modernise the equipment
of Laboratorio Chile. It has already been mentioned
that this enterprise had been acquired by the Manual
Workers Fund many years earlier. Now, under the
impulse of the Ministry of Health, its share capital was
considerably increased, the capital being provided by
social security institutions and the SNS. This
facilitated its modernisation and enlargement. Impor-
tant in this respect was the setting up of an
independent department for quality control, appro-
priately staffed and equipped for this task. In parallel
with this unit for producing pharmaceutical products
another public enterprise, the Instituto Bacteriológico
(today incorporated in Laboratorio Chile), was used
to manufacture common vaccines and antitoxins, as
well as penicillin and chloramphenicol. Thus Chile
built up its stated-owned production capacity for
pharmaceuticals.
Laboratorio Chile entered a field with a large number
of established enterprises: well over 50 pharmaceutical
producers. Although the majority of these were
nationally owned, two thirds of the 25 largest
producers were subsidiaries of transnational cor-
porations (TNC5). About half of the latter were North
American, the rest were European. Between them they
produced almost all the drugs for domestic
consumption in Chile, with the TNC subsidiaries
importing the active ingredients from their parent
companies and the national firms doing so from
different producers in Western and Eastern Europe.
Only very few drugs were imported as finished
products because of their special technical character-
istics or production costs (for example insulin,
gamma-globulin, poliomyelitis vaccine, and anti-
cancer drugs). In spite of this situation, Laboratorio
Chile eventually established itself as a leading
enterprise, both in terms of production and of
domestic sales. It started producing the first batch of
about 20 products listed in the NF after the latter's
legal approval.
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Private Industry Confronts the National
Formulary
Once the government's pharmaceutical policy had
been given wide publicity in the country and was even
beginning to be discussed abroad [Business Inter-
national 1968], the Ministry of Health called a meeting
of all the pharmaceutical firms operating in the
country, both national and multinational. Represent-
atives of almost all firms attended this meeting. It was
the occasion at which they were officially informed of
the new policy, whose implementation was about to
start with the delivery of the first NF products to the
country's pharmacies.
The reasons for proceeding with the new policy were
explained. It was pointed out that one of its important
aims was to safeguard the people's health, but that
economic considerations were no less central. The
policy was intended to provide economic protection
for the consumers, particularly those with low
incomes, and for the health care services whose
budgets were greatly affected by the rising cost of
drugs. These objectives, it was stressed, could not be
achieved if the public sector did not have its own
productive capacity; hence Laboratorio Chile had
been provided with considerable resources which
placed it in a privileged position. It was now capable of
manufacturing products of the highest quality, and its
capacity could be rapidly expanded to meet all needs.
Nevertheless, soit was emphasised during the meeting,
the Ministry wished to give private industry the
opportunity of collaborating in this highly significant
project. This collaboration would also be in the
government's interest, given that it aimed to see all the
drugs included in the NF produced, as soon as
possible, in sufficient volume to provide a satisfactory
domestic supply.
It was made very clear that all public sector health care
services, and not only hospitals, would henceforth be
supplied exclusively with NF drugs. Any private sector
firm prepared to participate in the production of one
or more NF generic products would also be allowed to
market its own equivalent proprietary brand without
being subjected to price controls; this would be on the
understanding that the company would produce the
generic brand concerned according to NF specifi-
cations, at an agreed level of output, and in
competition with Laboratorio Chile or any other
pharmaceutical enterprise. For example: were Roche
to agree to produce NF chiordiazepoxide capsules
10 mg, it would be at liberty to market its Librium
capsules 10 mg at its own price.
The reaction of those present at the meeting was
evasive. The TNCs were convinced that the
government was heading for failure. On its part, the
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government was convinced that it could only put the
TNCs under pressure in the battle over drug prices by
providing the essential drugs competitively as
generics, backed up by the NF.
As the first NF products were becoming available in
the country's pharmacies, a supportive leading article
appeared in the official bulletin of the Chilean Medical
Association, whose representatives had participated
in the Commission that elaborated the NF. It stated:
'This represents a positive step forward in the
country's public health. It has momentous significance,
as it helps simplify prescribing and substantially
diminishes the cost of drugs - which directly benefits
the needy classes' [Colegio Médico de Chile 1969].
The support of the Medical Association was seen,
from the start, as crucial to the success of the policy. Its
own channels of communication with the country's
physicians could become for them the most effective
and important source of drug information, giving
them sober, scientific, and independent facts on the
prescribing practices likely to be of greatest benefit to
their patients. Generic products could thus be
promoted, and the all-pervasive publicity for
proprietary brands neutralised. In addition, as most
physicians worked part time in the public sector, they
would have a chance to familiarise themselves with the
management of generic products, as these would
henceforth be compulsory there.
Towards the end of 1969, a second batch of 30 further
NF products were added to those already on the
market. Table 1 lists some examples to give an idea of
the economic importance of the whole venture for the
consumer.
The International Health Organisations
Ignore the Experience
In July 1969 the World Health Assembly met in
Boston, USA. In one of the plenary sessions the
Chilean delegate outlined the country's pharmaceutical
policy and its achievements to date. A detailed
analysis was presented, and emphasis was placed on
the central aim of reducing the cost of those drugs
defined as essential, in order to make an impact on the
expenditure pattern in hospitals and on the cost of
personal health care. In this connection reference was
made to the study which had examined the pattern of
personal expenditure on drugs for different social
classes (cited above). It was also said that the
unjustified increase in the consumption of pharma-
ceuticals had been causing concern to the government,
especially because of the emergence of a new
pathology of adverse reactions to drugs, which could
be attributed at least partly to self-medication. The
new legislation was also meant to deal with these
Table I
Comparative prices of some national formulary
and equivalent proprietary drugs ¡n 1969
US $1 = E° 1336
issues, and in general to help bring about a
rationalisation of the use of pharmaceutical products.
These questions were not being taken up effectively at
the time by WHO or by its regional organisation in the
Americas, the Pan American Health Organisation
(PAHO). It was only in the late 1970s that these, and
other international organisations, began to show a
serious concern for these matters.2 At the time PAHO
was preoccupied with a scheme to establish a reference
laboratory, which would help member countries
control the quality of drugs, and it was agreed in 1969
to establish such a laboratory as soon as possible in
Montevideo. But this was not the most important issue
of the complex of policy problems relating to
pharmaceuticals. It would have been more sensible if
PAHO had supported the idea of a formulary of
generic drugs and promoted it within WHO. This
might have brought forward work on the list of
essential drugs, which in the event did not see the light
of day till almost 10 years later [WHO 19771.
Some Notes on the Allende Period
During the three years of President Allende's
government, pharmaceutical policies remained in
2Editors' note: see article by Patel in this issue.
their essentials the same as those of the previous
period. The production of Laboratorio Chile
continued to increase: from 500 mn units in 1970 to
757 mn in 1972. Sixty per cent of the items on the list
were by then available in the pharmacies. Nevertheless,
progress was slower than had been anticipated for the
period 1971 to 1973. The NF Commission was
changed, and the pace of making new NF drugs
available to the public, and of expanding production,
fell off during 1972-73. The health sector was
experiencing the widespread turmoil that affected all
public services at that time. Fortunately the efficient
secretariat of the Commission was left unchanged, and
the Commission continued to give advice on the
licencing of drugs.
The mass media continued to comment on what was
still a novelty; though not uncritical, that comment
was on the whole favourable and encouraging. A
feature in the Sunday magazine of the country's
largest quality newspaper (of conservative persuasion)
was not atypical:
'While the NF is reducing the prices of the most
used drugs, only some doctors prescribe them...'
'Controversial changes in the health field are being
provoked by more than one hundred generics
affordable by all .
'A public health specialist suggests that health
shouldn't be the object of profit . . . Of course the
NF does not restrict the freedom of doctors in the
hospitals: doctors prescribe drugs, not product
names.. . The ideas that inspired the NF are quite
consistent with medical ethics, as they help to give
more and better services to the community . .
'The NF enables people to spend less on drugs, and
that must be good for health. The money saved by
patients returns to their families in the form of
better nutrition, clothing or leisure time, and all of
these are related to health . . .' [El Mercurio 19721.
Regression under the Military Regime
In September 1973 the armed forces overthrew the
elected government of President Allende. The first
Minister of Health of the military government was an
outstanding physician and member of the Faculty of
Medicine of the University of Chile, who also held
high rank in the Air Force. While he remained in office
he supported the pharmaceutical policy based on the
NF. However, pressures against the NF made their
appearance after the first minister was replaced by
successive generals and the government imposed its
free market policies on the country. The existing
regulations were relaxed, and the marketing of new
drugs - imported as well as domestically produced
- was made easier. The NF Commission itself was
abolished in 1975. Since then the updating of the NF
has been undertaken by officials in the Ministry of
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NF Proprietary
E° E°
Phenytoin sodium inj. (100 mg) 1.90
'Epamin' 11.00
Phytomenadione ini. (10 mg) 8.50
'Konakion' 19.69
Prednisone tabs. (5 mg) 4.00
'Meticorten' 13.20
Dipyrone tabs. (300 mg) 2.20
'Conmel' (324 mg) 6.23
Suiphamethoxypyridazine tabs.
(500 mg) 2.60
'Lederkyn' 13.80
Health. It has been reduced to a simple listing of drugs
as the descriptive sections on such therapeutic group
- so useful for prescribers - have been omitted. The
NF now also lacks the scientific standing conferred on
it earlier by the professional qualifications of the
Commission's members.
With the relaxation of the procedures for introducing
new drugs into the market came a loosening of the
regulations affecting pharmacies. As a result,
pharmacies sprang up like mushrooms in the mid and
late 1970s. The free market illusion suggested that a
massive supply would lead to widespread competition
and thereby to price reductions. Needless to say, this
did not happen: drug prices are not established in the
retail market but earlier through the control of
production, promotion and distribution. And the
failure of Chile's free market policies have not left the
pharmacies unaffected: over the past year, bank-
ruptcies have been an almost daily occurrence.
It is no wonder that these policies also affected
Laboratorio Chile. By 1975 it was well behind its
production schedule, and less than 50 per cent of the
products included in the NF were being manufactured.
Even so, those products that were made available
commercially had price tags that were considerably
lower than those of their proprietary equivalents. Not
atypical were percentage differences of 45 and 73 per
cent between NF ampicillin capsules and the two most
widely sold brand name equivalents; for diazepam the
differences were 48 and 263 per cent. The price gap for
some drugs was much higher: the cheapest proprietary
propanolol tablets on the market were 289 per cent
more expensive than their NF equivalent and another
brand cost over 10 times as much as the generic
[Ministério de Salud 1978J. The savings made by the
generic drug policy continue to be of the greatest
importance to the public health services.
Final Comments
It is clear that the objectives of the NF have been only
partially achieved, and that in some respects there has
even been regression. It is not surprising that little
collaboration was forthcoming from the pharma-
ceutical TNCs; but even without such collaboration, a
determined national government could have had a
very substantial impact. Such determination has not
existed in Chile over the last 10 years.
The benefits of a national formulary will be limited as
long as production of the drugs on its list is
inadequate. Without enough financial support a
public sector producer like Laboratorio Chile cannot
expand the market for generics, a market that is of
little interest to the private companies. Without an
authority such as the NF Commission to play an
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official role in the process of decision-making
concerning import, production, marketing and
quality control of pharmaceuticals, the public cannot
be adequately protected from the anarchy of a free
market in drugs. Without a strong professional body
which can promote a pattern of prescribing based on
low-cost drugs, doctors will be inordinately influenced
by the publicity of the pharmaceutical companies. All
these condittions are absent in Chile today. To
elaborate briefly on only one of these issues: the
military government has reduced the power of the
Chilean Medical Association as it has done with all
such professional bodies - potentially independent
centres of power that cannot be tolerated. The
participation of the Association in the formulation of
the country's health policy is now marginal.
So far, the government has accepted the survival of the
NF, though apparently half-heartedly. But the truth is
that Laboratorio Chile remains constantly in the
government economists' sights. There have been many
rumours that the government was about to call for
bids so that the enterprise might be transferred to the
private sector. So far that has not happened, perhaps
in part because those working in it have voiced their
objections to this course of action, which would
automatically mean the end of the NF as an effective
policy instrument.
Since the installation of the military government the
country's economic policies have been based on the
principles of the free market. The experience of the
past 12 months or so, when the Chilean economy
spiralled down into a state of near-collapse, shows that
even in macroeconomic terms these principles do not
work. How much less are they relevant to the market
in pharmaceuticals. Economic anarchy in this sector
has extremely serious consequences for the health of
the population of a developing country such as Chile.
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